{"symbol":"MRK","fiscalQuarter":"Q2-2026","reportDate":"2026-08-04","reportTime":"BMO","status":"upcoming","company":{"name":"Merck & Co., Inc.","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/MRK/earnings/Q2-2026","preBrief":{"companySnapshot":"Merck & Co., Inc. (MRK) is a leading global healthcare company that develops and produces pharmaceuticals, vaccines, and animal health products. With a market cap of $293 billion, Merck plays a crucial role in the healthcare sector, focusing on innovative treatments and therapies that address significant medical needs.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to increase sales and market share, critical for sustaining long-term growth.","consensus":"N/A"},{"name":"Pipeline Developments","why":"Updates on new drug approvals or advancements in clinical trials can significantly impact future revenue potential.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1 2026, Merck reported an EPS of -$1.28, which was better than analysts' expectations of -$1.51, resulting in a positive surprise of 15.46%. However, the stock fell 1.60% the following day, indicating mixed investor sentiment.","promises":[]},"wallStreetExpectations":{"summary":"Overall, investors are cautiously optimistic about Merck's upcoming earnings report, especially following the positive surprise last quarter. However, concerns remain about the company's ability to maintain growth amidst competitive pressures.","bullCase":"If Merck can demonstrate strong revenue growth and positive developments in its drug pipeline, it could lead to a significant upward revision in earnings expectations.","bearCase":"Conversely, if the company reports disappointing revenue or fails to provide clear guidance on future growth, it could lead to a sharp decline in stock price."},"optionsSignal":{"impliedMove":"11.6%","context":"The options market is pricing in a significant move of 11.6%, indicating that traders expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+15.46%","reaction":"-1.60%"},{"quarter":"Q4-2025","epsSurprise":"+0.59%","reaction":"+2.18%"},{"quarter":"Q3-2025","epsSurprise":"+9.32%","reaction":"-0.35%"},{"quarter":"Q2-2025","epsSurprise":"+4.67%","reaction":"-1.70%"},{"quarter":"Q1-2025","epsSurprise":"+3.06%","reaction":"+1.40%"},{"quarter":"Q4-2024","epsSurprise":"+1.53%","reaction":"-9.07%"},{"quarter":"Q3-2024","epsSurprise":"+4.39%","reaction":"-2.39%"},{"quarter":"Q2-2024","epsSurprise":"+5.75%","reaction":"-9.81%"}],"pivotalQuestions":[{"question":"What is the expected revenue growth for the upcoming quarter?","whyItMatters":"Revenue growth is crucial for assessing the company's ability to expand its market presence and meet investor expectations."},{"question":"What updates can management provide on the drug pipeline?","whyItMatters":"Insights into the pipeline can significantly influence future revenue potential and investor confidence."}],"thesisBreakLevels":{"bullTrigger":"A revenue growth rate of 5% or higher would confirm the bullish outlook.","bearTrigger":"If revenue growth falls below 2%, it would support the bearish case.","context":"This quarter's performance hinges on the company's ability to deliver strong revenue growth and updates on its drug pipeline."},"scenarioPlaybook":{"beatAndRaise":"If Merck beats expectations and raises guidance, history suggests the stock could see an average one-day move of +2.67%, confirming positive investor sentiment.","inLineCautious":"If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess their outlook.","miss":"Should the company miss expectations, history suggests an average one-day move of -2.67%, likely leading to a negative reaction from investors."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The market may be underestimating the potential for Merck's new drug approvals to drive significant revenue growth this quarter.","supportingPoints":["The company's recent pipeline advancements suggest a stronger than expected performance.","Options are pricing in a larger move than historical averages, indicating heightened investor uncertainty.","Insider buying activity suggests confidence in the company's future prospects."],"riskToConsensus":"If the drug pipeline shows unexpected strength, it could challenge current revenue projections."},"whatToListenFor":["Updates on new drug approvals and their expected impact on revenue.","Management's outlook on competitive pressures in the pharmaceutical market.","Any changes in guidance regarding revenue growth for the upcoming quarters.","Insights into the performance of existing products and their market share.","Discussion on cost management strategies and their effect on profitability."],"metaDescription":"Merck (MRK) reports Q2 2026 earnings August 4. Investors are watching for revenue growth and pipeline updates."}}